Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
ConversionCommon Stock | 137,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 4 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 404,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
PurchaseCommon Stock | 69,880 | $5.00 | $349,400.00 |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 3 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 267,581 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
PurchaseCommon Stock | 197,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 2 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 197,701 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:37 UTC |
Fletcher Aaron G.L.10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
BIOS Fund III, LP10% owner
BIOS Fund III QP, LP10% owner
BIOS Fund III NT, LP10% owner
BIOS Equity Partners III, LP10% owner
BIOS Azitra Co-Invest I, LP10% owner
|
SaleConvertible Notes | 77,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074424 · tm2319609-1_4seq1.xml · nonDerivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner BIOS Fund III, LP · CIK 0001791917 · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner BIOS Azitra Co-Invest I, LP · CIK 0001769262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 0 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 397,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 34 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Azitra Co-Invest I, LP Disclosed balance after: 0 Underlying: Common Stock · 397,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 22,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 33 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 0 Underlying: Common Stock · 22,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 101,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 32 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 0 Underlying: Common Stock · 101,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 170,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 31 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 0 Underlying: Common Stock · 170,272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 412,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 30 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 0 Underlying: Common Stock · 412,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 52,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 29 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 0 Underlying: Common Stock · 52,078 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries A-1 Convertible Preferred Stock · Derivative | 232,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 28 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 0 Underlying: Common Stock · 232,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F6 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 799,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 27 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I, LP Disclosed balance after: 0 Underlying: Common Stock · 799,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries A Convertible Preferred Stock · Derivative | 467,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 26 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I QP, LP Disclosed balance after: 0 Underlying: Common Stock · 467,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F5 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 130,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 25 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 0 Underlying: Common Stock · 130,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 808,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 24 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 0 Underlying: Common Stock · 808,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 123,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · derivative · entry 23 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 0 Underlying: Common Stock · 123,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 436,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 21 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Azitra Co-Invest I, LP Disclosed balance after: 436,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 25,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 20 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 137,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 111,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 19 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 111,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 188,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 18 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 1,023,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 834,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 17 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 834,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 57,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 16 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 313,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 255,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 15 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 255,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.10 per share, after making certain anti-dilution adjustments. The Series A-1 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 799,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 14 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I, LP Disclosed balance after: 799,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 467,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 13 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund I QP, LP Disclosed balance after: 467,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series A Convertible Preferred Stock automatically converted into one share of common stock of the Issuer upon the closing of the Issuer's IPO. The Series A Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 144,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 12 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 426,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
PurchaseCommon Stock | 73,708 | $5.00 | $368,540.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 11 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 282,239 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
PurchaseCommon Stock | 208,531 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 10 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 208,531 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
SaleConvertible Notes | 82,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 9 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 0 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 896,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 8 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 2,643,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
PurchaseCommon Stock | 456,412 | $5.00 | $2,282,060.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 7 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 1,747,670 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
PurchaseCommon Stock | 1,291,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 6 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 1,291,258 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
SaleConvertible Notes | 509,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 5 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 0 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
ConversionCommon Stock | 137,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 4 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 404,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
PurchaseCommon Stock | 69,880 | $5.00 | $349,400.00 |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 3 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 267,581 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
PurchaseCommon Stock | 197,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 2 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 197,701 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:38 UTC |
Kreis Leslie W.10% owner
Cavu Advisors, LLC10% owner
Cavu Management, LP10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
Bios Equity Partners, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II NT, LP10% owner
BIOS Fund II QP, LP10% owner
Bios Equity Partners II, LP10% owner
|
SaleConvertible Notes | 77,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-074425 · tm2319609-2_4seq1.xml · nonDerivative · entry 1 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 0 F1 · price: The convertible note automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to $2.50 per share. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I") and Bios Fund I QP, LP ("Bios Fund I QP"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Azitra Co-invest I, LP ("Bios Azitra Co-invest"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. F3 · ownership.nature: Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Fund III, Bios Fund III QP, Bios Fund III NT and Bios Azitra Co-invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:28 UTC |
Whitfill TravisDirector · Chief Operating Officer
|
GrantCommon Stock | 250 | $5.00 | $1,250.00 |
DisclosureSEC source: 0001493152-23-022296 · ownership.xml · nonDerivative · entry 1 Whitfill Travis · CIK 0001830178 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250 Read SEC document |
| June 21, 2023 Filed Jun 24, 2023 00:39 UTC |
Salva Francisco D.Director · President and CEO
|
GrantCommon Stock | 5,000 | $5.00 | $25,000.00 |
DisclosureSEC source: 0001493152-23-022316 · ownership.xml · nonDerivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 21, 2023 Filed Jun 26, 2023 10:15 UTC |
McClary AndrewDirector
|
ConversionUnsecured convertible note · Derivative | Not disclosed | $2.50 | $42,437.00 |
DisclosureSEC source: 0001493152-23-022334 · ownership.xml · derivative · entry 4 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 16,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F2 · derivative.exercise_date: The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F4 · derivative.expiration_date: Not applicable. F2 · balance_after: The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F3 · ownership.direct: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 26, 2023 10:15 UTC |
McClary AndrewDirector
|
ConversionSeries A-1 Convertible Preferred Stock, par value $0.0001 · Derivative | 249,474 | $2.50 | $623,685.00 |
DisclosureSEC source: 0001493152-23-022334 · ownership.xml · derivative · entry 3 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common stock · 42,347 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F1 · derivative.exercise_date: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F4 · derivative.expiration_date: Not applicable. F1 · balance_after: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 26, 2023 10:15 UTC |
McClary AndrewDirector
|
ConversionCommon stock, $0.0001 par value | 16,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-022334 · ownership.xml · nonDerivative · entry 2 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 16,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The unsecured convertible note, including principal and accrued interest in the amount of $105,867.50, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 26, 2023 10:15 UTC |
McClary AndrewDirector
|
ConversionCommon stock, $0.0001 par value | 42,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-022334 · ownership.xml · nonDerivative · entry 1 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 42,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 29, 2023 20:56 UTC Amendment |
McClary AndrewDirector
|
ConversionUnsecured convertible promissory note · Derivative | Not disclosed | $0.00 Strike: $2.50 | $106,093.00 |
DisclosureSEC source: 0001493152-23-022948 · ownership.xml · derivative · entry 4 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 42,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The unsecured convertible note, including principal and accrued interest in the amount of $106,093.15, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F2 · derivative.expiration_date: The unsecured convertible note, including principal and accrued interest in the amount of $106,093.15, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 29, 2023 20:56 UTC Amendment |
McClary AndrewDirector
|
ConversionSeries A-1 Convertible Preferred Stock, par value $0.0001 · Derivative | 32,030 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001493152-23-022948 · ownership.xml · derivative · entry 3 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common stock · 249,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $4.8146 per share. F1 · derivative.expiration_date: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $4.8146 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 29, 2023 20:56 UTC Amendment |
McClary AndrewDirector
|
ConversionCommon stock, $0.0001 par value | 42,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-022948 · ownership.xml · nonDerivative · entry 2 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 291,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The unsecured convertible note, including principal and accrued interest in the amount of $106,093.15, automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $2.50 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jun 29, 2023 20:56 UTC Amendment |
McClary AndrewDirector
|
ConversionCommon stock, $0.0001 par value | 249,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-022948 · ownership.xml · nonDerivative · entry 1 McClary Andrew · CIK 0001972173 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 249,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A preferred stock automatically converted into the Issuer's common stock upon the completion of the Issuer's IPO at the conversion price of $4.8146 per share. F3 · ownership.nature: The securities are held by KdT Ventures Fund I, LP, of which Mr. McClary is the managing partner. Read SEC document |
| June 21, 2023 Filed Jul 24, 2023 17:51 UTC |
BAYER HEALTHCARE LLC10% owner
Bayer US Holding LP10% owner
Bayer World Investments B.V.10% owner
BAYER AKTIENGESELLSCHAFT10% owner
|
ConversionSeries B Convertible Preferred Stock · Derivative | 1,307,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000065 · primary_doc.xml · derivative · entry 2 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,307,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document |
| June 21, 2023 Filed Jul 24, 2023 17:51 UTC |
BAYER HEALTHCARE LLC10% owner
Bayer US Holding LP10% owner
Bayer World Investments B.V.10% owner
BAYER AKTIENGESELLSCHAFT10% owner
|
ConversionCommon Stock | 1,307,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-23-000065 · primary_doc.xml · nonDerivative · entry 1 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,307,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.